Pilot study shows significant reduction in Type 2 Diabetes insulin dependency

NOIDA, India - Jan. 3, 2020 - PRLog -- IDF statistics show that Indian diabetic population is going to 134.2 million by 2045 and without an effective treatment pattern, insulin dependency will drastically rise for the patients.

In T2DM, the pancreas insulin production decreases drastically and a loss of glycemic regulation follows besides deregulated levels of HbA1C and C-peptide levels.

In the study, researchers suggest that bone marrow-derived mononuclear cells (BM-MNCs) can be a potential therapy candidate against T2DM owing to many prior significant results of BM-MNCs in regulating glycemic control and pancreatic functions.

"This open-labeled randomized study was conducted to evaluate the efficacy and long-term management of autologous BM-MNCs transplantation in T2DM cases and we hypothesized C-peptide increase along with a significant reduction in blood glucose, insulin dependency, and HbA1c levels with our therapy", says Dr. Sachin Kadam, CTO, Advancells.

A total of 10 patients were selected based on an exclusive inclusion criterion set and the baseline evaluation of BMI, blood glucose (fasting and postprandial), and FPI levels were done by the medical team, prior to the treatment. After bone marrow extraction and processing, enriched BM-MNCs were infused into the patients' anterior pancreaticoduodenal artery via 5F catheterization. Post-transplantation, patients were subjected to personalized medication patterns based on the treatment and were followed up for a 12-month period to ensure long-term management.

During the follow-up period, the patients showed improved body metabolism and showed a significant decrease in their blood glucose and HbA1c levels, besides an increase in FPI and C-peptide levels. As per the reports, 80% of the T2DM patients showed a ≥ 50% reduction in insulin dependency.

Although the 12-month follow-up study showed a significant glycemic regulation in the T2DM patients, this study included few limitations based on firsthand data collection and cohort size. As per Dr. Kadam, "The most important one is the geographical distribution of patients which limit the firsthand data collection during given time point. Thus, we had to rely on the data provided by the patients, making it more retrospective than prospective to establish a causal-effect relationship between the patient parameters evaluated. Larger scale clinical studies in the future will validate the accuracy and comprehensively assess the efficacy of our treatment regime."

Publication Information

https://crimsonpublishers.com/iterm/pdf/ITERM.000517.pdf

About Advancells

Advancells is one of the pioneering stem cell-based companies in India, which is focused on Regenerative therapeutics for tissue-specific disorders.